China SXT Pharmaceuticals Secures $12 Million in Direct Offering

The deal involves the sale of 8 million Class A ordinary shares at a price of $1.50 per share. Investors will also receive an equal number of warrants, exercisable at $1.50 per share with a one-year expiration. These warrants include a zero-cash exercise option, allowing holders to acquire up to nine additional Class A shares per warrant, potentially increasing the total impact of the issuance.

Univest Securities, LLC is managing the transaction as the sole placement agent. Beyond the initial $12 million, the agreement grants investors a 30-day window to purchase an additional $12 million in securities under identical terms. The offering follows a shelf registration statement that became effective in December 2025. The company intends to use the proceeds to support its ongoing research, development, and manufacturing operations for its traditional medicine product line.